Apatinib for Inoperable Advanced Chondrosarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-01

Study Completion Date

2020-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated chondrosarcoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

NCT03811054

Non Small Cell Lung Cancer

UNKNOWN PHASE2

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

NCT03359018

Progression-free Survival Overall Survival Clinical Benefit Rate +1 more

COMPLETED PHASE2

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT03050411

Nonsmall Cell Lung Cancer

UNKNOWN PHASE1

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC

NCT03428022

NSCLC Apatinib EGFR-TKI

UNKNOWN PHASE3

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

NCT03180476

Nasopharyngeal Neoplasms

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Efficacy Toxicity, Drug

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apatinib Arm

Group Type EXPERIMENTAL

Apatinib Mesylate

Intervention Type DRUG

Apatinib orally 500mg once daily half an hour after meal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apatinib Mesylate

Apatinib orally 500mg once daily half an hour after meal

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) histologically confirmed high-grade sarcoma;
* 2\) initial treatment in the orthopedic oncology departments of the two affiliated hospitals of Peking University;
* 3\) tumors not amenable to curative treatment or inclusion in clinical trials;
* 4\) unresectable local advanced lesions or multiple metastatic lesions that could not be cured by local therapy;
* 5\) measurable lesions according to Response Evaluation Criteria for Solid Tumors (RECIST1.1) ;
* 6\) Eastern Cooperative Oncology Group performance status 0 or 1;
* 7\) acceptable hematologic, hepatic, and renal function.

Exclusion Criteria

* had central nervous system metastasis;
* had other kinds of malignant tumors at the same time; had cardiac insufficiency or arrhythmia;
* had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++ and so on;
* had pleural or peritoneal effusion that needs to be handled by surgical treatment;
* combined with other infections or wounds;
* pregnant or breastfeeding.

Eligible Sex

ALL

Accepts Healthy Volunteers

No